Executive Management Team
Christopher Anzalone, Ph.D., Chief Executive Officer
Dr. Anzalone also is the CEO of Calando Research Corporation. Prior to his leadership of Calando, Dr. Anzalone was CEO and founder of the Benet Group, a private equity firm focused on creating and building new nanobiotechnology companies from university-generated science. Prior to Benet, Dr. Anzalone was a partner at the Washington, D.C.-based private equity firm Galway Partners, LLC, where he was in charge of sourcing, structuring, and building new business ventures and was founding CEO of NanoInk, Inc., a leading nanolithography company. Dr. Anzalone holds a Ph.D. and M.A. in Biology from UCLA and a B.A. in Government from Lawrence University.
Thomas Schluep, Sc.D., Chief Scientific Officer
Dr. Schluep is an expert in translating delivery system and therapy innovations into pharmaceutical and biotechnology product candidates. Dr. Schluep was the Chief Scientific Officer of Insert Therapeutics, prior to its merger with Calando, where he headed drug discovery and development programs for the polymeric delivery system Cyclosert and the IT-101 candidate. While at Insert, he drove IT-101 from the laboratory to Phase I clinical trial in less than two years. Prior to joining Insert, Dr. Schluep was responsible for the non-viral gene therapy program at Canji, Inc., a wholly-owned subsidiary of Schering-Plough. At Canji, he successfully led an interdisciplinary team of scientists in their efforts to develop synthetic gene delivery vehicles for the systemic treatment of cancer with the p53 tumor suppressor gene. Prior to Canji, Dr. Schluep was a post-doctoral associate at the department of Chemical Engineering at the Massachusetts Institute of Technology. He received his Sc.D. in Process Engineering in 1995 and an MS in Biotechnology in 1989, both from the Swiss Federal Institute of Technology in Zurich, Switzerland.
Jeremy Heidel, Consultant – Oligonucleotide Delivery
Dr. Heidel has expertise in the areas of: (i) synthesis and characterization of polymeric delivery vehicles and their formulations, (ii) identification of siRNA target sites and the design of potent RNAi molecules, and (iii) the design and execution of in vitro and in vivo experiments to evaluate formulation efficacy. He was the first to show that synthetic siRNA molecules do not elicit immune responses in animals.Dr. Heidel earned his bachelor’s degrees in Chemical Engineering and Biology from MIT and his M.S. and Ph.D. degrees in Chemical Engineering from Caltech.He performed his doctoral thesis research on targeted, systemic, non-viral delivery of siRNA in the laboratory of Dr. Mark Davis.
Board of Directors
Christopher Anzalone, Ph.D., CEO of Calando, serves as chairman of the Board and Director of Calando.
Bruce Given, M.D.
Dr. Given is a healthcare products consultant and the Principal of Bruce Given Consulting. Prior to establishing his consulting practice, Dr. Given was President and Chief Executive Officer of Encysive Pharmaceuticals Inc., which subsequently was acquired by Pfizer. Prior to joining Encysive, he was with Johnson & Johnson for nine years, serving in several capacities including as President, International, Ortho-Clinical Diagnostics and as Group Vice President, Head of U.S. Marketing & Sales, Research & Development for Janssen Pharmaceutica, Inc. Dr. Given has held various executive and senior management positions at Sandoz Pharma Ltd., Sandoz Research Institute, and Schering-Plough Corporation. Prior to entering the pharmaceutical industry, he was on the medical faculty at the University of Chicago. Dr. Given currently serves on the Board of Directors for ICON Plc, BioHouston, and for the Texas Life Science Center. He is a member of the Technology Review Committee of MD Anderson Medical Center, and is past Chairman of the Rider University Scientific Advisory Board. Dr. Given is board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications. Dr. Given’s honors include the Franklin McLean Research Award from the University of Chicago, election to Alpha Omega Alpha, and the Provost Award from Colorado State University.
Mostafa Analoui, Ph.D.
Dr. Analoui is actively involved in investment, management, and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. Currently, he serves as head of Healthcare and Life Science at The Livingston Group, a specialty investment firm located in New York, NY and as Senior Vice President of Business Development at Charlesson Pharmaceuticals. Previously he was the Senior Director at Pfizer Inc. Global Research and Development, where he led the platform technology mission for clinical development and the commercial division in areas including medical imaging, diagnostics computational medicine, knowledge management, and non-invasive measurement monitoring. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research at Indiana University, where he still serves as an adjunct faculty member, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. Dr. Analouialso was President and CEO of Therametric Technology Inc. Dr. Analoui has served on various scientific, regulatory, and business advisory committees and boards and has authored over 130 publications, including journal articles, book chapters, and technical reports. He currently serves as a board member of VirtualScopics (Nasdaq: VSCP), BPT Pharma, BEACON (Biomedical Engineering Alliance and CONsortium), and NanoBusiness Alliance. Dr. Analoui holds a Ph.D. in engineering from Purdue University.
R. Bruce Stewart, Executive Chairman of Calando Research Corporation
Prior to his involvement with Calando, Mr. Stewart was the founder and served as Chairman and President of Acacia Research Corporation. Prior to Acacia, Mr. Stewart was the President of Annandale Corporation. He also was a licensed principal of Annandale Securities, Inc., a licensed broker-dealer.
Edward W. Frykman
Mr. Frykman also is a director of Calando Research Corporation. He retired from his position as an Account Executive with Crowell, Weedon & Co. in 1992, and before that served as Senior Vice President of L.H. Friend & Co. Both Crowell, Weedon & Co. and L.H. Friend & Co. are investment brokerage firms located in Southern California.In addition, Mr. Frykman was a Senior Account Executive with Shearson Lehman Hutton, where he served as the Manager of the Los Angeles Regional Retail Office of E. F. Hutton & Co.